Yes, Dr
Finan B, Yang B, Ottaway N, Stemmer K, Mller TD, Yi C-X, et al
GLP-1 therapies like Ozempic have also been shown to lower the risk of heart and kidney disease, leading to additional FDA approvals for heart and kidney protection
Such uses should only be considered within the context of clinical trials or after careful discussion of the limited evidence and potential risks with a qualified healthcare provider
This design offers structured opportunities to make earlier decisions when the intervention shows a significant benefit and improves efficiency in research by allowing adjustments in the trial design to be made compared with traditional, fixed-period RCTs
Some patients maintain more weight loss, especially those who made substantial lifestyle changes during treatment